Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Leukemia 9Leukemia, Myeloid, Acute 8Burkitt Lymphoma 7Recurrence 4Leukemia, Biphenotypic, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Down Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1Vincristine 1Methotrexate 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Cytarabine 1Calcium Dobesilate 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypersensitivity × asparaginase erwinia chrysanthemi recombinant × Other hematologic neoplasm × Clear all
NCT00928200 2019-02-19

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Terminated
1 enrolled 7 charts
LymphoidOther hematologic neoplasm

Hypersensitivity, Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡